Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: BIOLOGICAL: Pembrolizumab|DRUG: Olaparib|DRUG: Carboplatin|DRUG: Gemcitabine
Sponsor: Merck Sharp & Dohme LLC